Axel W.A. Baltzer

Axel W.A. Baltzer

Auto-generated profile, based on publicly available information

Axel W.A. Baltzer

Königsallee, Centre for Molecular Orthopaedics Düsseldorf

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2013 in Orthopedic Reviews
Verified
Journal Article
Open access
PDF file
ABAxel W.A. Baltzer
Axel W.A. Baltzer
MOMartin S. Ostapczuk
Martin S. Ostapczuk
DSDaniel Stosch
Daniel Stosch
FSFlorian Seidel
Florian Seidel
MGMarkus Granrath
Markus Granrath
The purpose of the present study was to investigate the effect of intra-articular injections of autologous conditioned serum on human hip osteoarthritis and to test whether a potential treatment effect might be increased by additional injections of steroids and the recombinant interleukin-1 receptor antagonist protein anakinra. We compared the effects of autologous conditioned serum 46 hip osteoarthritis patients), autologous conditioned serum+cortisone (56 patients), and autologous conditioned serum+cortisone+recombinant interleukin-1 receptor antagonist protein (17 patients) in a retrospective clinical study by means of the Visual Analogue Scale for pain (pre- vs post-treatment). Over 14 months, treatment resulted in a large, statistically significant improvement for patients in all three groups, independent of the severity of osteoarthritis. Neither cortisone nor cortisone+recombinant interleukin-1 receptor antagonist protein increased the beneficial treatment effect over and above the effect of autologous conditioned serum alone. Autologous conditioned serum successfully reduces pain in hip osteoarthritis. In severe hip osteoarthritis, the sole application of autologous conditioned serum can be even more beneficial than the combination of autologous conditioned serum with steroids.

2 February 2016 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
ABAxel W.A. Baltzer
Axel W.A. Baltzer
MOMartin S. Ostapczuk
Martin S. Ostapczuk
DSDaniel Stosch
Daniel Stosch

1 November 2016 in Orthopaedics & Traumatology: Surgery & Research
Verified
Journal Article
Closed access
ABA.W.A. Baltzer
A.W.A. Baltzer
MOM.S. Ostapczuk
M.S. Ostapczuk
HTH.P. Terheiden
H.P. Terheiden
HMH.R. Merk
H.R. Merk

2 January 2012 in Orthopedic Reviews
Verified
Journal Article
Open access
PDF file
ABAxel W.A. Baltzer
Axel W.A. Baltzer
MOMartin S. Ostapczuk
Martin S. Ostapczuk
DSDaniel Stosch
Daniel Stosch
MGMarkus Granrath
Markus Granrath
Although the clinical potential of bone morphogenetic proteins (BMPs) has been known for decades, their use in humans has only been approved for a limited number of orthopaedic conditions. Promising results in animals demonstrate the utility of BMP-2 in regional bone repair without using osteoconductors. To our knowledge, no comparable human case has been described. We report the case of a 50- year-old who suffered a femoral neck fracture. After 9 months of extensive treatment, he was still not pain-free. The following open-wedge osteotomy resulted in a therapy-resistant delayed union. We therefore conducted 4 computer tomography-guided injections of recombinant human (rh) BMP-2 into the bone gap. No osteoconductor was employed. Six weeks later, there was a 55-60% defect filling. Followup examination showed a complete union of the bone defect. Our case report shows that in a complicated delayed union rhBMP-2 can be successfully used to induce bone formation without any osteoconductor.

2 May 2017 in Zeitschrift für Rheumatologie
Verified
Journal Article
Closed access
PDF file
ABA. W. A. Baltzer
A. W. A. Baltzer
DSD. Stosch
D. Stosch
FSF. Seidel
F. Seidel
MOM. S. Ostapczuk
M. S. Ostapczuk

21 April 2023 in Frontiers in Surgery
Verified
Journal Article
Open access
ABAxel W. Baltzer
Axel W. Baltzer
RCRita Casadonte
Rita Casadonte
AKAlexei Korff
Alexei Korff
LBLea Merline Baltzer
Lea Merline Baltzer
KKKatharina Kriegsmann
Katharina Kriegsmann
JKJörg Kriegsmann
Jörg Kriegsmann
Objective: To investigate the in vivo biological effects of leukocyte-poor platelet-rich plasma (LpPRP) treatment in human synovial layer to establish the cellular basis for a prolonged clinical improvement.Methods: Synovial tissues (n = 367) were prospectively collected from patients undergoing arthroscopic surgery. Autologous-conditioned plasma, LpPRP, was injected into the knees of 163 patients 1–7 days before surgery to reduce operative trauma and inflammation, and to induce the onset of regeneration. A total of 204 patients did not receive any injection. All samples were analyzed by mass spectrometry imaging. Data analysis was evaluated by clustering, classification, and investigation of predictive peptides. Peptide identification was done by tandem mass spectrometry and database matching.Results: Data analysis revealed two major clusters belonging to LpPRP-treated (LpPRP-1) and untreated (LpPRP-0) patients. Classification analysis showed a discrimination accuracy of 82%–90%. We identified discriminating peptides for CD45 and CD29 receptors (receptor-type tyrosine-protein phosphatase C and integrin beta 1), indicating an enhancement of musculoskeletal stem cells, as well as an enhancement of lubricin, collagen alpha-1-(I) chain, and interleukin-receptor-17-E, dampening the inflammatory reaction in the LpPRP-1 group following LpPRP injection.Conclusions: We could demonstrate for the first time that injection therapy using “autologic-conditioned biologics” may lead to cellular changes in the synovial membrane that might explain the reported prolonged beneficial clinical effects. Here, we show in vivo cellular changes, possibly based on muscular skeletal stem cell alterations, in the synovial layer. The gliding capacities of joints might be improved by enhancing of lubricin, anti-inflammation by activation of interleukin-17 receptor E, and reduction of the inflammatory process by blocking interleukin-17.